Brain Atrophy

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 309 Experts worldwide ranked by ideXlab platform

Peter A Calabresi - One of the best experts on this subject based on the ideXlab platform.

  • revisiting Brain Atrophy and its relationship to disability in multiple sclerosis
    PLOS ONE, 2012
    Co-Authors: Navid Shiee, Pierrelouis Bazin, Kathleen M Zackowski, Sheena K Farrell, Daniel M Harrison, Scott D Newsome, John N Ratchford, Brian S Caffo, Peter A Calabresi
    Abstract:

    Background Brain Atrophy is a well-accepted imaging biomarker of multiple sclerosis (MS) that partially correlates with both physical disability and cognitive impairment.

  • retinal nerve fiber layer is associated with Brain Atrophy in multiple sclerosis
    Neurology, 2008
    Co-Authors: Eliza Gordonlipkin, Gary Cutter, B Chodkowski, Daniel S Reich, Seth A Smith, Mathew Pulicken, Laura J Balcer, Elliot M Frohman, Peter A Calabresi
    Abstract:

    Gordon-Lipkin et al. reported the correlation between the thickness of the retinal nerve fiber layer (RNFL) and Brain parenchymal Atrophy in multiple sclerosis (MS).1 These results confirm our previous study where we found correlation between RNFL thickness and gray matter and white matter volume.2 Using two different approaches for measuring Brain Atrophy, both studies demonstrate that the thickness of the RNFL correlates with Brain Atrophy. In both cases, we studied patients at the early to medium stage of the disease, indicating that the Atrophy identified, both at the head of the optic nerve and in the Brain, is …

Rohit Bakshi - One of the best experts on this subject based on the ideXlab platform.

  • Rate of Brain Atrophy in Benign vs Early Multiple Sclerosis
    JAMA Neurology, 2009
    Co-Authors: Susan A. Gauthier, Rohit Bakshi, Annika M. Berger, Zsuzsanna Liptak, Yang Duan, Svetlana Egorova, Guy J. Buckle, Bonnie I. Glanz, Samia J. Khoury, Howard L. Weiner
    Abstract:

    Background Benign multiple sclerosis (MS) is defined by minimal or no disability after many years of observation, therefore a less degenerative disease process is suspected to be present in this subset of patients. Objective To compare Brain Atrophy rates in patients with long-standing benign MS vs typical early MS. Design A longitudinal prospective cohort study and a retrospective database review. Setting An academic MS center. Patients Thirty-nine patients with clinically defined benign MS and an age-matched group of 40 patients with early relapsing-remitting MS. Main Outcome Measures Baseline demographic, treatment, Brain magnetic resonance imaging measures, and annualized Atrophy rates, derived from serial Brain parenchymal fraction measurements across 2 years, were compared. Results In the baseline analysis, patients with benign MS were matched to the early MS group on age, sex, treatment with immunomodulatory therapy, T2 lesion volume, and Brain parenchymal fraction. The mean (SD) annualized Brain Atrophy rate in patients with benign MS (−0.16% [0.51%]) was lower than that in patients with early MS (−0.46% [0.72%]) ( P  = .02). The difference remained significant after controlling for age, sex, and treatment ( P  = .04). Conclusions Serial magnetic resonance imaging revealed a low 2-year rate of Brain Atrophy in patients with clinically benign MS, suggesting a less prominent degenerative component in its pathogenesis than in patients with typical early MS. Identification of patients with a low rate of Brain Atrophy may indicate a benign course.

  • the measurement and clinical relevance of Brain Atrophy in multiple sclerosis
    Lancet Neurology, 2006
    Co-Authors: Robert A Bermel, Rohit Bakshi
    Abstract:

    Summary Brain Atrophy has emerged as a clinically relevant component of disease progression in multiple sclerosis. Progressive loss of Brain tissue bulk can be detected in vivo in a sensitive and reproducible manner by MRI. Clinical studies have shown that Brain Atrophy begins early in the disease course. The increasing amount of data linking Brain Atrophy to clinical impairments suggest that irreversible tissue destruction is an important determinant of disease progression to a greater extent than can be explained by conventional lesion assessments. In this review, we will summarise the proposed mechanisms contributing to Brain Atrophy in patients with multiple sclerosis. We will critically discuss the wide range of MRI-based methods used to quantify regional and whole-Brain-volume loss. Based on a review of current information, we will summarise the rate of Atrophy among phenotypes for multiple sclerosis, the clinical relevance of Brain Atrophy, and the effect of disease-modifying treatments on its progression.

Navid Shiee - One of the best experts on this subject based on the ideXlab platform.

Hugo Vrenken - One of the best experts on this subject based on the ideXlab platform.

  • whole Brain Atrophy rate and csf biomarker levels in mci and ad a longitudinal study
    Neurobiology of Aging, 2010
    Co-Authors: J D Sluimer, Hugo Vrenken, Femke H Bouwman, M A Blankenstein, Frederik Barkhof, Wiesje M Van Der Flier, P Scheltens
    Abstract:

    Abstract Objectives To assess associations between cerebrospinal fluid (CSF) biomarker levels and MRI-based whole-Brain Atrophy rate in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Methods We included 99 patients (47 AD, 29 MCI, 23 controls) who underwent lumbar puncture at baseline and repeat MRI. A subgroup of 48 patients underwent a second lumbar puncture. CSF levels of beta-amyloid1–42 (Aβ1–42), tau and tau phosphorylated at threonine-181 (P-tau181), and whole-Brain Atrophy rate were measured. Results Across groups, baseline Aβ1–42 and tau were modestly associated with whole-Brain Atrophy rate. Adjusted for age, sex and diagnosis, we found no association between Aβ1–42 or tau, and whole-Brain Atrophy rate. By contrast, high CSF levels of P-tau181 showed a mild association with a lower whole-Brain Atrophy rate in AD but not in controls or MCI patients. Finally, whole-Brain Atrophy rate was associated with change in MMSE, but change in CSF biomarker levels was not. Conclusions Whole-Brain Atrophy rate and CSF levels of Aβ1–42, tau or P-tau181 provide complementary information in patients with MCI and AD.

  • whole Brain Atrophy rate and cognitive decline longitudinal mr study of memory clinic patients
    Radiology, 2008
    Co-Authors: J D Sluimer, P Scheltens, W M Van Der Flier, Frederik Barkhof, Giorgos B Karas, Hugo Vrenken
    Abstract:

    Purpose: To prospectively determine whole-Brain Atrophy rate in mild cognitive impairment (MCI) and Alzheimer disease (AD) and its association with cognitive decline, and investigate the risk of progression to dementia in initially nondemented patients given baseline Brain volume and whole-Brain Atrophy rate. Materials and Methods: This study was IRB approved; written informed consent was obtained; and included 65 AD patients (38 women, 27 men; age, 52–81 years), 45 MCI patients (22 women, 23 men; age, 56–80 years), 27 patients with subjective complaints (12 women, 15 men; age, 50–87 years), and 10 healthy controls (six women, four men; age, 53–80 years). Two magnetic resonance (MR) images were acquired at average interval of 1.8 years ± 0.7 (standard deviation). Baseline Brain volume and whole-Brain Atrophy rates were measured on three-dimensional T1-weighted MR images (1.0 T; single slab, 168 sections; matrix size, 256 × 256; field of view, 250 mm; voxel size, 1 × 1 × 1.5 mm; repetition time msec/echo t...

  • Whole-Brain Atrophy rate in Alzheimer disease: identifying fast progressors.
    Neurology, 2008
    Co-Authors: J D Sluimer, Hugo Vrenken, M A Blankenstein, P Scheltens, F Barkhof, W M Van Der Flier
    Abstract:

    To assess which baseline clinical and MRI measures influence whole-Brain Atrophy rates, measured from serial MR imaging. We recruited 65 patients with Alzheimer disease (mean +/- SD age 70 +/- 8 y, 58% women, Mini-Mental State Examination [MMSE] 22 +/- 5), scanned with an average interval of 1.7 +/- 0.6 years. Whole-Brain Atrophy rates were used as outcome measure. Baseline normalized Brain volume, hippocampal volume, and whole-Brain Atrophy rates were measured using three-dimensional T1-weighted imaging. The influence of age, sex, apolipoprotein E genotype (APOE), baseline MMSE, baseline hippocampal volume, and baseline normalized Brain volume on whole-Brain Atrophy rates was assessed using linear regression. The mean whole-Brain Atrophy rate was -1.9 +/- 0.9% per year. In the multivariate model, younger age (beta [SE] = 0.03 [0.01]; p = 0.04), absence of APOE epsilon 4 (beta [SE] = 0.61 [0.28]; p = 0.03), and a low MMSE (beta [SE] = 0.11 [0.03]; p < 0.001) were associated with a higher whole-Brain Atrophy rate. Furthermore, a relatively spared hippocampus predicted faster decline for patients with a smaller baseline Brain volume (p = 0.09), and with a lower MMSE (p = 0.07). Finally, a smaller Brain volume was associated with a higher rate of Atrophy in younger patients (p = 0.03). Our results suggest it is possible to characterize a subgroup of patients with Alzheimer disease (AD) who are at risk of faster loss of Brain volume. Patients with more generalized, rather than focal hippocampal Atrophy, who often have an onset before the age of 65, and are APOE epsilon 4 negative, seem to be at risk of faster whole-Brain Atrophy rates than the more commonly seen patients with AD, who are older, are APOE epsilon 4 positive, and have pronounced hippocampal Atrophy.

  • Whole-Brain Atrophy rate in Alzheimer disease: identifying fast progressors
    Neurology, 2008
    Co-Authors: J D Sluimer, Hugo Vrenken, M A Blankenstein, P Scheltens, F Barkhof, W M Van Der Flier
    Abstract:

    Objective: To assess which baseline clinical and MRI measures influence whole-Brain Atrophy rates, measured from serial MR imaging. Methods: We recruited 65 patients with Alzheimer disease (mean ± SD age 70 ± 8 y, 58% women, Mini-Mental State Examination [MMSE] 22 ± 5), scanned with an average interval of 1.7 ± 0.6 years. Whole-Brain Atrophy rates were used as outcome measure. Baseline normalized Brain volume, hippocampal volume, and whole-Brain Atrophy rates were measured using three-dimensional T1-weighted imaging. The influence of age, sex, apolipoprotein E genotype (APOE), baseline MMSE, baseline hippocampal volume, and baseline normalized Brain volume on whole-Brain Atrophy rates was assessed using linear regression. Results: The mean whole-Brain Atrophy rate was −1.9 ± 0.9% per year. In the multivariate model, younger age (β [SE] = 0.03 [0.01]; p = 0.04), absence of APOE e4 (β [SE] = 0.61 [0.28]; p = 0.03), and a low MMSE (β [SE] = 0.11 [0.03]; p p = 0.09), and with a lower MMSE ( p = 0.07). Finally, a smaller Brain volume was associated with a higher rate of Atrophy in younger patients ( p = 0.03). Conclusions: Our results suggest it is possible to characterize a subgroup of patients with Alzheimer disease (AD) who are at risk of faster loss of Brain volume. Patients with more generalized, rather than focal hippocampal Atrophy, who often have an onset before the age of 65, and are APOE e4 negative, seem to be at risk of faster whole-Brain Atrophy rates than the more commonly seen patients with AD, who are older, are APOE e4 positive, and have pronounced hippocampal Atrophy.

  • Whole-Brain Atrophy rate in Alzheimer disease: Identifying fast progressors
    Neurology, 2008
    Co-Authors: J D Sluimer, Hugo Vrenken, M A Blankenstein, P Scheltens, F Barkhof, W M Van Der Flier
    Abstract:

    OBJECTIVE: To assess which baseline clinical and MRI measures influence whole-Brain Atrophy rates, measured from serial MR imaging. METHODS: We recruited 65 patients with Alzheimer disease (mean ± SD age 70 ± 8 y, 58% women, Mini-Mental State Examination [MMSE] 22 ± 5), scanned with an average interval of 1.7 ± 0.6 years. Whole-Brain Atrophy rates were used as outcome measure. Baseline normalized Brain volume, hippocampal volume, and whole-Brain Atrophy rates were measured using three-dimensional T1-weighted imaging. The influence of age, sex, apolipoprotein E genotype (APOE), baseline MMSE, baseline hippocampal volume, and baseline normalized Brain volume on whole-Brain Atrophy rates was assessed using linear regression. RESULTS: The mean whole-Brain Atrophy rate was -1.9 ± 0.9% per year. In the multivariate model, younger age (β [SE] = 0.03 [0.01]; p = 0.04), absence of APOE ε4 (β [SE] = 0.61 [0.28]; p = 0.03), and a low MMSE (β [SE] = 0.11 [0.03]; p < 0.001) were associated with a higher whole-Brain Atrophy rate. Furthermore, a relatively spared hippocampus predicted faster decline for patients with a smaller baseline Brain volume (p = 0.09), and with a lower MMSE (p = 0.07). Finally, a smaller Brain volume was associated with a higher rate of Atrophy in younger patients (p = 0.03). CONCLUSIONS: Our results suggest it is possible to characterize a subgroup of patients with Alzheimer disease (AD) who are at risk of faster loss of Brain volume. Patients with more generalized, rather than focal hippocampal Atrophy, who often have an onset before the age of 65, and are APOE ε4 negative, seem to be at risk of faster whole-Brain Atrophy rates than the more commonly seen patients with AD, who are older, are APOE ε4 positive, and have pronounced hippocampal Atrophy. ©2008AAN Enterprises, Inc

P Scheltens - One of the best experts on this subject based on the ideXlab platform.

  • whole Brain Atrophy rate and csf biomarker levels in mci and ad a longitudinal study
    Neurobiology of Aging, 2010
    Co-Authors: J D Sluimer, Hugo Vrenken, Femke H Bouwman, M A Blankenstein, Frederik Barkhof, Wiesje M Van Der Flier, P Scheltens
    Abstract:

    Abstract Objectives To assess associations between cerebrospinal fluid (CSF) biomarker levels and MRI-based whole-Brain Atrophy rate in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Methods We included 99 patients (47 AD, 29 MCI, 23 controls) who underwent lumbar puncture at baseline and repeat MRI. A subgroup of 48 patients underwent a second lumbar puncture. CSF levels of beta-amyloid1–42 (Aβ1–42), tau and tau phosphorylated at threonine-181 (P-tau181), and whole-Brain Atrophy rate were measured. Results Across groups, baseline Aβ1–42 and tau were modestly associated with whole-Brain Atrophy rate. Adjusted for age, sex and diagnosis, we found no association between Aβ1–42 or tau, and whole-Brain Atrophy rate. By contrast, high CSF levels of P-tau181 showed a mild association with a lower whole-Brain Atrophy rate in AD but not in controls or MCI patients. Finally, whole-Brain Atrophy rate was associated with change in MMSE, but change in CSF biomarker levels was not. Conclusions Whole-Brain Atrophy rate and CSF levels of Aβ1–42, tau or P-tau181 provide complementary information in patients with MCI and AD.

  • whole Brain Atrophy rate and cognitive decline longitudinal mr study of memory clinic patients
    Radiology, 2008
    Co-Authors: J D Sluimer, P Scheltens, W M Van Der Flier, Frederik Barkhof, Giorgos B Karas, Hugo Vrenken
    Abstract:

    Purpose: To prospectively determine whole-Brain Atrophy rate in mild cognitive impairment (MCI) and Alzheimer disease (AD) and its association with cognitive decline, and investigate the risk of progression to dementia in initially nondemented patients given baseline Brain volume and whole-Brain Atrophy rate. Materials and Methods: This study was IRB approved; written informed consent was obtained; and included 65 AD patients (38 women, 27 men; age, 52–81 years), 45 MCI patients (22 women, 23 men; age, 56–80 years), 27 patients with subjective complaints (12 women, 15 men; age, 50–87 years), and 10 healthy controls (six women, four men; age, 53–80 years). Two magnetic resonance (MR) images were acquired at average interval of 1.8 years ± 0.7 (standard deviation). Baseline Brain volume and whole-Brain Atrophy rates were measured on three-dimensional T1-weighted MR images (1.0 T; single slab, 168 sections; matrix size, 256 × 256; field of view, 250 mm; voxel size, 1 × 1 × 1.5 mm; repetition time msec/echo t...

  • Whole-Brain Atrophy rate in Alzheimer disease: identifying fast progressors.
    Neurology, 2008
    Co-Authors: J D Sluimer, Hugo Vrenken, M A Blankenstein, P Scheltens, F Barkhof, W M Van Der Flier
    Abstract:

    To assess which baseline clinical and MRI measures influence whole-Brain Atrophy rates, measured from serial MR imaging. We recruited 65 patients with Alzheimer disease (mean +/- SD age 70 +/- 8 y, 58% women, Mini-Mental State Examination [MMSE] 22 +/- 5), scanned with an average interval of 1.7 +/- 0.6 years. Whole-Brain Atrophy rates were used as outcome measure. Baseline normalized Brain volume, hippocampal volume, and whole-Brain Atrophy rates were measured using three-dimensional T1-weighted imaging. The influence of age, sex, apolipoprotein E genotype (APOE), baseline MMSE, baseline hippocampal volume, and baseline normalized Brain volume on whole-Brain Atrophy rates was assessed using linear regression. The mean whole-Brain Atrophy rate was -1.9 +/- 0.9% per year. In the multivariate model, younger age (beta [SE] = 0.03 [0.01]; p = 0.04), absence of APOE epsilon 4 (beta [SE] = 0.61 [0.28]; p = 0.03), and a low MMSE (beta [SE] = 0.11 [0.03]; p < 0.001) were associated with a higher whole-Brain Atrophy rate. Furthermore, a relatively spared hippocampus predicted faster decline for patients with a smaller baseline Brain volume (p = 0.09), and with a lower MMSE (p = 0.07). Finally, a smaller Brain volume was associated with a higher rate of Atrophy in younger patients (p = 0.03). Our results suggest it is possible to characterize a subgroup of patients with Alzheimer disease (AD) who are at risk of faster loss of Brain volume. Patients with more generalized, rather than focal hippocampal Atrophy, who often have an onset before the age of 65, and are APOE epsilon 4 negative, seem to be at risk of faster whole-Brain Atrophy rates than the more commonly seen patients with AD, who are older, are APOE epsilon 4 positive, and have pronounced hippocampal Atrophy.

  • Whole-Brain Atrophy rate in Alzheimer disease: identifying fast progressors
    Neurology, 2008
    Co-Authors: J D Sluimer, Hugo Vrenken, M A Blankenstein, P Scheltens, F Barkhof, W M Van Der Flier
    Abstract:

    Objective: To assess which baseline clinical and MRI measures influence whole-Brain Atrophy rates, measured from serial MR imaging. Methods: We recruited 65 patients with Alzheimer disease (mean ± SD age 70 ± 8 y, 58% women, Mini-Mental State Examination [MMSE] 22 ± 5), scanned with an average interval of 1.7 ± 0.6 years. Whole-Brain Atrophy rates were used as outcome measure. Baseline normalized Brain volume, hippocampal volume, and whole-Brain Atrophy rates were measured using three-dimensional T1-weighted imaging. The influence of age, sex, apolipoprotein E genotype (APOE), baseline MMSE, baseline hippocampal volume, and baseline normalized Brain volume on whole-Brain Atrophy rates was assessed using linear regression. Results: The mean whole-Brain Atrophy rate was −1.9 ± 0.9% per year. In the multivariate model, younger age (β [SE] = 0.03 [0.01]; p = 0.04), absence of APOE e4 (β [SE] = 0.61 [0.28]; p = 0.03), and a low MMSE (β [SE] = 0.11 [0.03]; p p = 0.09), and with a lower MMSE ( p = 0.07). Finally, a smaller Brain volume was associated with a higher rate of Atrophy in younger patients ( p = 0.03). Conclusions: Our results suggest it is possible to characterize a subgroup of patients with Alzheimer disease (AD) who are at risk of faster loss of Brain volume. Patients with more generalized, rather than focal hippocampal Atrophy, who often have an onset before the age of 65, and are APOE e4 negative, seem to be at risk of faster whole-Brain Atrophy rates than the more commonly seen patients with AD, who are older, are APOE e4 positive, and have pronounced hippocampal Atrophy.

  • Whole-Brain Atrophy rate in Alzheimer disease: Identifying fast progressors
    Neurology, 2008
    Co-Authors: J D Sluimer, Hugo Vrenken, M A Blankenstein, P Scheltens, F Barkhof, W M Van Der Flier
    Abstract:

    OBJECTIVE: To assess which baseline clinical and MRI measures influence whole-Brain Atrophy rates, measured from serial MR imaging. METHODS: We recruited 65 patients with Alzheimer disease (mean ± SD age 70 ± 8 y, 58% women, Mini-Mental State Examination [MMSE] 22 ± 5), scanned with an average interval of 1.7 ± 0.6 years. Whole-Brain Atrophy rates were used as outcome measure. Baseline normalized Brain volume, hippocampal volume, and whole-Brain Atrophy rates were measured using three-dimensional T1-weighted imaging. The influence of age, sex, apolipoprotein E genotype (APOE), baseline MMSE, baseline hippocampal volume, and baseline normalized Brain volume on whole-Brain Atrophy rates was assessed using linear regression. RESULTS: The mean whole-Brain Atrophy rate was -1.9 ± 0.9% per year. In the multivariate model, younger age (β [SE] = 0.03 [0.01]; p = 0.04), absence of APOE ε4 (β [SE] = 0.61 [0.28]; p = 0.03), and a low MMSE (β [SE] = 0.11 [0.03]; p < 0.001) were associated with a higher whole-Brain Atrophy rate. Furthermore, a relatively spared hippocampus predicted faster decline for patients with a smaller baseline Brain volume (p = 0.09), and with a lower MMSE (p = 0.07). Finally, a smaller Brain volume was associated with a higher rate of Atrophy in younger patients (p = 0.03). CONCLUSIONS: Our results suggest it is possible to characterize a subgroup of patients with Alzheimer disease (AD) who are at risk of faster loss of Brain volume. Patients with more generalized, rather than focal hippocampal Atrophy, who often have an onset before the age of 65, and are APOE ε4 negative, seem to be at risk of faster whole-Brain Atrophy rates than the more commonly seen patients with AD, who are older, are APOE ε4 positive, and have pronounced hippocampal Atrophy. ©2008AAN Enterprises, Inc